뉴스벤징가
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
· 발표
기사 요약
Jazz Pharma (JAZZ) revenue growth driven by Ziihera adoption as 1L treatment for HER2+ GEA, says BofA analyst.
기사 원문에서 발췌했어요.Jazz Pharma (JAZZ) revenue growth driven by Ziihera adoption as 1L treatment for HER2+ GEA, says BofA analyst.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…